schliessen

Filtern

 

Bibliotheken

Encapsulation of recombinant adenovirus into alginate microspheres circumvents vector-specific immune response

Pre-existing immunity against adenoviruses may compromise the efficacy of adenoviral vectors for vaccination and gene therapy. The purpose of this study was to determine whether encapsulation of adenovirus recombinants into biodegradable alginate microparticles could circumvent the vector-specific i... Full description

Journal Title: Gene therapy December 2002, Vol.9(24), pp.1722-9
Main Author: Sailaja, G
Other Authors: Hogenesch, H , North, A , Hays, J , Mittal, S K
Format: Electronic Article Electronic Article
Language: English
Subjects:
ID: ISSN: 0969-7128 ; PMID: 12457287 Version:1
Link: http://pubmed.gov/12457287
Zum Text:
SendSend as email Add to Book BagAdd to Book Bag
Staff View
recordid: medline12457287
title: Encapsulation of recombinant adenovirus into alginate microspheres circumvents vector-specific immune response
format: Article
creator:
  • Sailaja, G
  • Hogenesch, H
  • North, A
  • Hays, J
  • Mittal, S K
subjects:
  • Alginates
  • Biocompatible Materials
  • Genetic Vectors
  • Adenoviridae -- Genetics
ispartof: Gene therapy, December 2002, Vol.9(24), pp.1722-9
description: Pre-existing immunity against adenoviruses may compromise the efficacy of adenoviral vectors for vaccination and gene therapy. The purpose of this study was to determine whether encapsulation of adenovirus recombinants into biodegradable alginate microparticles could circumvent the vector-specific immune response. Mice were immunized either intranasally (i.n.) or intraperitoneally (i.p.) with human adenovirus type 5 (HAd5), resulting in the development of virus-specific antibodies. Immunized and nai;ve mice were inoculated with AdCA36lacZ (an E1-deleted HAd5 recombinant containing the bacterial beta-galactosidase (LacZ) gene), encapsulated (E) into alginate microparticles, or nonencapsulated (NE) ie, as a virus suspension. LacZ expression in animals immunized once (1x) or twice (2x) with HAd5 and subsequently inoculated with NE-AdCA36lacZ (NE-Z) was significantly (P
language: eng
source:
identifier: ISSN: 0969-7128 ; PMID: 12457287 Version:1
fulltext: fulltext
issn:
  • 09697128
  • 0969-7128
url: Link


@attributes
ID603333575
RANK0.07
NO1
SEARCH_ENGINEprimo_central_multiple_fe
SEARCH_ENGINE_TYPEPrimo Central Search Engine
LOCALfalse
PrimoNMBib
record
control
sourcerecordid12457287
sourceidmedline
recordidTN_medline12457287
sourceformatXML
sourcesystemPC
pqid18649663
display
typearticle
titleEncapsulation of recombinant adenovirus into alginate microspheres circumvents vector-specific immune response
creatorSailaja, G ; Hogenesch, H ; North, A ; Hays, J ; Mittal, S K
ispartofGene therapy, December 2002, Vol.9(24), pp.1722-9
identifierISSN: 0969-7128 ; PMID: 12457287 Version:1
subjectAlginates ; Biocompatible Materials ; Genetic Vectors ; Adenoviridae -- Genetics
descriptionPre-existing immunity against adenoviruses may compromise the efficacy of adenoviral vectors for vaccination and gene therapy. The purpose of this study was to determine whether encapsulation of adenovirus recombinants into biodegradable alginate microparticles could circumvent the vector-specific immune response. Mice were immunized either intranasally (i.n.) or intraperitoneally (i.p.) with human adenovirus type 5 (HAd5), resulting in the development of virus-specific antibodies. Immunized and nai;ve mice were inoculated with AdCA36lacZ (an E1-deleted HAd5 recombinant containing the bacterial beta-galactosidase (LacZ) gene), encapsulated (E) into alginate microparticles, or nonencapsulated (NE) ie, as a virus suspension. LacZ expression in animals immunized once (1x) or twice (2x) with HAd5 and subsequently inoculated with NE-AdCA36lacZ (NE-Z) was significantly (P<0.001) reduced compared to those levels observed in NE-Z inoculated nai;ve mice, suggesting that the immune response against...
languageeng
source
version6
lds50peer_reviewed
links
openurl$$Topenurl_article
backlink$$Uhttp://pubmed.gov/12457287$$EView_this_record_in_MEDLINE/PubMed
openurlfulltext$$Topenurlfull_article
addlink$$Uhttp://exlibris-pub.s3.amazonaws.com/aboutMedline.html$$EView_the_MEDLINE/PubMed_Copyright_Statement
search
creatorcontrib
0Sailaja, G
1HogenEsch, H
2North, A
3Hays, J
4Mittal, S K
titleEncapsulation of recombinant adenovirus into alginate microspheres circumvents vector-specific immune response
descriptionPre-existing immunity against adenoviruses may compromise the efficacy of adenoviral vectors for vaccination and gene therapy. The purpose of this study was to determine whether encapsulation of adenovirus recombinants into biodegradable alginate microparticles could circumvent the vector-specific immune response. Mice were immunized either intranasally (i.n.) or intraperitoneally (i.p.) with human adenovirus type 5 (HAd5), resulting in the development of virus-specific antibodies. Immunized and nai;ve mice were inoculated with AdCA36lacZ (an E1-deleted HAd5 recombinant containing the bacterial beta-galactosidase (LacZ) gene), encapsulated (E) into alginate microparticles, or nonencapsulated (NE) ie, as a virus suspension. LacZ expression in animals immunized once (1x) or twice (2x) with HAd5 and subsequently inoculated with NE-AdCA36lacZ (NE-Z) was significantly (P<0.001) reduced compared to those levels observed in NE-Z inoculated nai;ve mice, suggesting that the immune response against...
subject
0Alginates
1Biocompatible Materials
2Genetic Vectors
3Adenoviridae -- Genetics
general
012457287
1English
2MEDLINE/PubMed (U.S. National Library of Medicine)
3MEDLINE/PubMed (NLM)
sourceidmedline
recordidmedline12457287
issn
009697128
10969-7128
rsrctypearticle
creationdate2002
addtitleGene therapy
searchscope
0medline
1nlm_medline
2MEDLINE
scope
0medline
1nlm_medline
2MEDLINE
lsr41200212
citationpf 1722 vol 9 issue 24
startdate20021201
enddate20021231
lsr30VSR-Enriched:[pqid, eissn, doi]
sort
titleEncapsulation of recombinant adenovirus into alginate microspheres circumvents vector-specific immune response
authorSailaja, G ; Hogenesch, H ; North, A ; Hays, J ; Mittal, S K
creationdate20021200
lso0120021200
facets
frbrgroupid3346876394481843102
frbrtype5
newrecords20190701
languageeng
creationdate2002
topic
0Alginates
1Biocompatible Materials
2Genetic Vectors
3Adenoviridae–Genetics
collectionMEDLINE/PubMed (NLM)
prefilterarticles
rsrctypearticles
creatorcontrib
0Sailaja, G
1Hogenesch, H
2North, A
3Hays, J
4Mittal, S K
jtitleGene Therapy
toplevelpeer_reviewed
delivery
delcategoryRemote Search Resource
fulltextfulltext
addata
aulast
0Sailaja
1Hogenesch
2North
3Hays
4Mittal
aufirst
0G
1H
2A
3J
4S K
au
0Sailaja, G
1Hogenesch, H
2North, A
3Hays, J
4Mittal, S K
atitleEncapsulation of recombinant adenovirus into alginate microspheres circumvents vector-specific immune response
jtitleGene therapy
risdate200212
volume9
issue24
spage1722
pages1722-9
issn0969-7128
formatjournal
genrearticle
ristypeJOUR
abstractPre-existing immunity against adenoviruses may compromise the efficacy of adenoviral vectors for vaccination and gene therapy. The purpose of this study was to determine whether encapsulation of adenovirus recombinants into biodegradable alginate microparticles could circumvent the vector-specific immune response. Mice were immunized either intranasally (i.n.) or intraperitoneally (i.p.) with human adenovirus type 5 (HAd5), resulting in the development of virus-specific antibodies. Immunized and nai;ve mice were inoculated with AdCA36lacZ (an E1-deleted HAd5 recombinant containing the bacterial beta-galactosidase (LacZ) gene), encapsulated (E) into alginate microparticles, or nonencapsulated (NE) ie, as a virus suspension. LacZ expression in animals immunized once (1x) or twice (2x) with HAd5 and subsequently inoculated with NE-AdCA36lacZ (NE-Z) was significantly (P<0.001) reduced compared to those levels observed in NE-Z inoculated nai;ve mice, suggesting that the immune response against...
pmid12457287
doi10.1038/sj.gt.3301858
eissn14765462
date2002-12